Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1

Vaccine

Volumn 22, Issue 8, 2004, Pages 1032-1046

  Jeffs, S A ^a,b   Goriup, S ^a   Kebble, B ^a   Crane, D ^a   Bolgiano, B ^a   Sattentau, Q ^b   Jones, S ^a   Holmes, H ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Glycoprotein; Oligomeric envelope; Vaccine

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; EPITOPE; GLYCOPROTEIN GP 140; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2G12; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHINESE HAMSTER; CLADISTICS; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; MALE; NONHUMAN; OLIGOMERIZATION; OVARY CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; RABBIT; VIRUS ISOLATION;

EID: 1242338175     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.08.042     Document Type: Article

References (50)

1. Moore J.P., Cao Y., Leu J., Qin L., Korber B., Ho D.D. Inter- and intraclade neutralisation of human immunodeficiency virus type 1: genetic clades do not correspond to neutralisation serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:1996;427-444.
2. Kostrikis L.G., Cao Y., Ngai H., Moore J.P., Ho D.D. Quantitative analysis of serum neutralisation of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F and I: lack of distinct correlation between neutralisation serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70:1996;445-458.
3. Weber J, Fenyo E-M, Beddows S, Kaleebu P, Bjorndal A, and the WHO Network for HIV Isolation and Characterisation. Neutralisation serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J Virol 1996;70:7827-32.
4. Bures R., Morris L., Williamson C.et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J. Virol. 76:2002;2233-2244.
5. Wyatt R., Kwong P.D., Desjardins E.W.et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:1998;705-710.
6. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterisation of long-term survivors of human immunodeficiency virus type 1 infection. New Engl. J. Med. 332:1995;201-208.
7. Stamatatos N.M., Mascola J.R., Kalyanaraman V.S.et al. Neutralising antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J. Virol. 72:1998;9656-9667.
8. Lu M., Blackow S., Kim P. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1995;1075-1085.
9. Lu M., Ji H., Shen S. Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion. J. Virol. 73:1999;4433-4438.
10. Broder C.C., Earl P.L., Long D., Abedon S.T., Moss B., Doms R.W. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 91:1994;11699-11703.
11. Earl P.L., Broder C.C., Long D.et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68:1994;3015-3026.
12. Earl P.L., Sugiura W., Montefiori D.C.et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J. Virol. 75:2001;645-653.
13. VanCott T.C., Mascola J.R., Kaminski R.W.et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:1997;4319-4330.
14. Yang X., Wyatt R., Sodroski J. Improved elicitation of neutralising antibodies against primary human immunodeficiency viruses by soluble stabilised envelope glycoprotein trimers. J. Virol. 75:2001;1165-1171.
15. Parren P.W., Wang M., Trkola A. Antibody-neutralisation resistant primary isolates of human immunodeficiency virus type 1. J. Virol. 72:1998;10270-10274.
16. Sattentau Q.J., Moore J.P. Human immunodeficiency virus type 1 neutralisation is determined by epitope exposure on the glycoprotein gp120 oligomer. J. Exp. Med. 182:1995;185-196.
17. Burton D.R. A vaccine for HIV-1: the antibody perspective. Proc. Natl. Acad. Sci. U.S.A. 94:1997;10018-10023.
18. Burton D.R., Moore J.P. Why do we not have an HIV vaccine and how can we make one? Nat. Med. 4:1998;495-498.
19. Srivastava I.K., Stamatatos L., Legg H.et al. Purification and characterisation of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J. Virol. 76:2002;2835-2847.
20. Burton D.R., Pyati J., Koduri R.et al. Efficient neutralisation of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1994;1024-1027.
21. Fouts T.R., Binley J.M., Trkola A., Robinson J.E., Moore J.P. Interaction of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV-1 isolate: relationship to neutralisation. AIDS Res. Hum. Retro. 4:1997;591-597.
22. Roben P., Moore J.P., Thali M., Sodroski J., Barbas C.F., Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralise human immunodeficiency virus type 1. J. Virol. 68:1994;4821-4828.
23. Trkola A., Purtscher M., Muster T.et al. Human monoclonal antibody 2G12 defines a distinctive neutralisation epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1996;1100-1108.
24. Gao F., Yue L., Craig S.et al. Genetic variation of HIV Type 1 in four World Health Organisation-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C and E. AIDS Res. Hum. Retro. 11:1994;1359-1367.
25. Sauermann U., Schneider J., Mous J.et al. Molecular cloning and characterisation of a German HIV-1 isolate. AIDS Res. Hum. Retro. 6:1990;813-823.
26. Jones D.H., McBride B.W., Roff M.A., Farrar G.H. Efficient purification and rigorous characterisation of a recombinant gp120 for vaccine studies. Vaccine. 13:1995;991-999.
27. Rhodes A.D., Spitali M., Hutchinson G., Rud E.W., Stephens P.E. Expression, characterization and purification of simian immunodeficiency virus soluble, oligomerised gp160 from mammalian cells. J. Gen. Virol. 75:1994;207-213.
28. Jeffs S.A., McKeating J., Lewis S.et al. Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. J. Gen. Virol. 77:1996;1403-1410.
29. Cockett M.I., Bebbington C.R., Yarranton G.T. The use of engineered EIA genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines. Nucleic Acids Res. 19:1991;319-325.
30. Chapman B.S., Thayer R.M., Vincent K.A., Haigwood N.I. Effect of intron A from human cytomegalovirus (Towne) intermediate early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 19:1991;3979-3986.
31. Buchacher A., Predl R., Strutzenberger K.et al. Generation of human monoclonal antibodies against HIV-1 proteins electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalisation. AIDS Res. Hum. Retro. 10:1990;359-369.
32. Mizuochi T., Spellman M.W., Larkin M., Solomon J., Basa L.J., Feizi T. Carbohydrate structures of the human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. Biochem. J. 254:1988;599-603.
33. 2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology. 248:1998;394-405.
34. Binley J.M., Sanders R.W., Las B.et al. A recombinant human immunodeficiency virus type I envelope glycoprotein complex stabilised by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74:2000;627-643.
35. Sanders R.W., Schiffner L., Master A.et al. Variable-loop-deleted variants of the human immunodeficiency virus type I envelope glycoprotein can be stabilised by an intermolecular disulfide bond between the gp120 and gp41 subunits. J. Virol. 74:2000;5091-5100.
36. Yang X., Florin L., Farzan M.et al. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J. Virol. 74:2000;4746-4754.
37. Yang X., Farzan M., Wyatt R., Sodroski J. Characterisation of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 74:2000;5716-5725.
38. Staropoli I., Chanel C., Girard M., Altmeyer R. Processing, stability and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate. J. Biol. Chem. 275:2000;35137-35145.
39. Balk S.S., Doms R.W., Doranz B.J. HIV and SIV gp120 binding does not predict coreceptor function. Virology. 259:1999;267-273.
40. Earl P.L., Broder C.C., Doms R.W., Moss B. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunisation with oligomeric envelope protein. J. Virol. 71:1997;2674-2684.
41. Edinger A.L., Blanpain C., Kuntsman K.J., Wolinsky S.M., Parmentier M., Doms R.W. Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains. J. Virol. 73:1999;4062-4073.
42. Richardson T.M., Stryjewski B.L., Broder C.C.et al. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J. Virol. 70:1996;753-762.
43. Binley J.M., Sanders R.W., Master A.et al. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 76:2002;2606-2616.
44. Berman P.W., Matthews T.J., Riddle L.et al. Neutralisation of multiple laboratory and clinical isolates of human immunodeficiency virus type I (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol. 66:1992;4464-4469.
45. Barnett S.W., Lu S., Srivastava I.et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralising antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75:2001;5526-5540.
46. + T-cell-depleted rhesus macaques. J. Virol. 75:2001;1547-1550.
47. Bjorndal A., Deng H., Jansson M.et al. Coreceptor usage of primary human immunodeficiency virus type I isolates varies according to biological phenotype. J. Virol. 71:1997;7478-7487.
48. WHO Network for HIV Isolation and Characterization. HIV Type 1 variation on World Health Organisation-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains, AIDS Res Hum Retro 1994;10:1327-43.
49. Gao F., Morrison S.G., Robertson D.L.et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. J. Virol. 70:1996;1651-1657.
50. Gurtler L.G., Hauser P.H., Erberle J.et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J. Virol. 68:1994;1581-1585.